Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
1(11%)
Results Posted
17%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
1
11%
Ph phase_1
8
89%

Phase Distribution

8

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
8(88.9%)
Phase 2Efficacy & side effects
1(11.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated1
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
85.7%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (88.9%)
Phase 21 (11.1%)

Trials by Status

terminated111%
completed667%
recruiting111%
withdrawn111%

Recent Activity

1 active trials
Showing 5 of 9
recruitingphase_1

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162
completedphase_1

A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

NCT00233506
withdrawnphase_1

Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.

NCT00226993
completedphase_1

CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

NCT00185965
terminatedphase_1

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

NCT01164514
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07221162Phase 1

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Recruiting
NCT00233506Phase 1

A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

Completed
NCT00226993Phase 1

Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.

Withdrawn
NCT00185965Phase 1

CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

Completed
NCT01164514Phase 1

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

Terminated
NCT00031278Phase 1

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

Completed
NCT00043407Phase 1

CPG 7909 in Patients Wih Stage IV Renal Cell Cancer

Completed
NCT00070629Phase 2

CPG 7909 Injection in Non-Small Cell Lung Cancer

Completed
NCT00320658Phase 1

Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9